The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
Open accessAbstract
BACKGROUND: Fingolimod (FTY720) is a new oral immunomodulating agent under evaluation for the treatment of relapsing multiple sclerosis. METHODS: We randomly assigned 281 patients to receive oral fingolimod, at a dose of 1.25 mg or 5.0 mg, or a placebo once daily, and we followed these patients for 6 months with magnetic resonance imaging (MRI) and clinical evaluations (core study, months 0 to 6). The primary end point was the total number of gadolinium-enhanced lesions recorded on T(1)-weighted MRI at monthly intervals for 6 months. In an extension study in which the investigators and patients remained unaware of the dose assignments (months 7 to 12), patients who received placebo underwent randomization again to one of the fingolimod doses. RESULTS: A total of 255 patients completed the core study. The median total number of gadolinium-enhanced lesions on MRI was lower with 1.25 mg of fingolimod (1 lesion, P<0.001) and 5.0 mg of fingolimod (3 lesions, P=0.006) than with placebo (5 lesions). The annualized relapse rate was 0.77 in the placebo group, as compared with 0.35 in the group given 1.25 mg of fingolimod (P=0.009) and 0.36 in the group given 5.0 mg of fingolimod (P=0.01). For the 227 patients who completed the extension study, the number of gadolinium-enhanced lesions and relapse rates remained low in the groups that received continuous fingolimod, and both measures decreased in patients who switched from placebo to fingolimod. Adverse events included nasopharyngitis, dyspnea, headache, diarrhea, and nausea. Clinically asymptomatic elevations of alanine aminotransferase levels were more frequent with fingolimod (10 to 12%, vs. 1% in the placebo group). One case of the posterior reversible encephalopathy syndrome occurred in the 5.0-mg group. Fingolimod was also associated with an initial reduction in the heart rate and a modest decrease in the forced expiratory volume in 1 second. CONCLUSIONS: In this proof-of-concept study, fingolimod reduced the number of lesions detected on MRI and clinical disease activity in patients with multiple sclerosis. Evaluation in larger, longer-term studies is warranted. (Clinicaltrials.gov numbers, NCT00333138 [core study] and NCT00235430 [ClinicalTrials.gov] [extension].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Self-citationAxonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., & Cyster, J. G. (2004) · Nature · doi:10.1038/nature02284 · Cited by 2,581
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
Immunology of multiple sclerosis
Sospedra, M., & Martin, R. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115707 · Cited by 2,149
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis
Smith, S. M., Zhang, Y., Jenkinson, M., Chen, J., Matthews, P. M., Federico, A., & De Stefano, N. (2002) · NeuroImage · doi:10.1006/nimg.2002.1040 · Cited by 2,013
Cited by
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Self-citationOral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Self-citationWymann, M. P., & Schneiter, R. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2335 · Cited by 1,291
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802670 · Cited by 1,017
Multiple sclerosis: a complicated picture of autoimmunity
McFarland, H. F., & Martin, R. (2007) · Nature Immunology · doi:10.1038/ni1507 · Cited by 985
LPA Receptors: Subtypes and Biological Actions
Choi, J. W., Herr, D. R., Noguchi, K., Yung, Y. C., Lee, C.-W., Mutoh, T., Lin, M.-E., Teo, S. T., Park, K. E., Mosley, A. N., et al. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105753 · Cited by 839
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Chun, J., & Hartung, H.-P. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cbf825 · Cited by 796
“Because fingolimod retains recently activated primary T cells and TCMs in lymphoid tissues, local immune responses that depend on these cells can be reduced or delayed, which may increase the risk of infections, including common viral infections such as colds and influenza.(31,71,90) However, memory immune responses t…”
BackgroundMolecular biology of bcr-abl1–positive chronic myeloid leukemia
Quintás-Cardama, A., & Cortes, J. (2009) · Blood · doi:10.1182/blood-2008-03-144790 · Cited by 745
Kappos, L., Li, D., Calabresi, P. A., O'Connor, P., Bar-Or, A., Barkhof, F., Yin, M., Leppert, D., Glanzman, R., Tinbergen, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61649-8 · Cited by 743
Self-citation“Inside-Out” Signaling of Sphingosine-1-Phosphate: Therapeutic Targets
Takabe, K., Paugh, S. W., Milstien, S., & Spiegel, S. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07113 · Cited by 718
Codega, P., Silva-Vargas, V., Paul, A., Maldonado-Soto, A. R., DeLeo, A. M., Pastrana, E., & Doetsch, F. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.039 · Cited by 634
The alliance of sphingosine-1-phosphate and its receptors in immunity
Rivera, J., Proia, R. L., & Olivera, A. (2008) · Nature Reviews Immunology · doi:10.1038/nri2400 · Cited by 616
Finding a way out: lymphocyte egress from lymphoid organs
Schwab, S. R., & Cyster, J. G. (2007) · Nature Immunology · doi:10.1038/ni1545 · Cited by 605
A regenerative approach to the treatment of multiple sclerosis
Deshmukh, V. A., Tardif, V., Lyssiotis, C. A., Green, C. C., Kerman, B., Kim, H. J., Padmanabhan, K., Swoboda, J. G., Ahmad, I., Kondo, T., et al. (2013) · Nature · doi:10.1038/nature12647 · Cited by 531
Brinkmann, V. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.04.006 · Cited by 528
Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis
Ishii, M., Egen, J. G., Klauschen, F., Meier-Schellersheim, M., Saeki, Y., Vacher, J., Proia, R. L., & Germain, R. N. (2009) · Nature · doi:10.1038/nature07713 · Cited by 515
Brinkmann, V. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00451.x · Cited by 438
Oo, M. L., Thangada, S., Wu, M.-T., Liu, C. H., Macdonald, T. L., Lynch, K. R., Lin, C.-Y., & Hla, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610318200 · Cited by 405
Sphingosine 1-Phosphate Receptor Signaling
Rosen, H., Gonzalez-Cabrera, P. J., Sanna, M. G., & Brown, S. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.072407.103733 · Cited by 404
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
Cohen, J. A., & Chun, J. (2011) · Annals of Neurology · doi:10.1002/ana.22426 · Cited by 393
Imaging outcomes for neuroprotection and repair in multiple sclerosis trials
Barkhof, F., Calabresi, P. A., Miller, D. H., & Reingold, S. C. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.41 · Cited by 378
Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors
Mullershausen, F., Zecri, F., Cetin, C., Billich, A., Guerini, D., & Seuwen, K. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.173 · Cited by 370
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
Mehling, M., Brinkmann, V., Antel, J., Bar-Or, A., Goebels, N., Vedrine, C., Kristofic, C., Kuhle, J., Lindberg, R. L. P., & Kappos, L. (2008) · Neurology · doi:10.1212/01.wnl.0000327609.57688.ea · Cited by 345
Self-citationMultiple sclerosis—a quiet revolution
Ransohoff, R. M., Hafler, D. A., & Lucchinetti, C. F. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.14 · Cited by 338
Thrombo-inflammation in acute ischaemic stroke — implications for treatment
Stoll, G., & Nieswandt, B. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0221-1 · Cited by 332
Myeloid microvesicles are a marker and therapeutic target for neuroinflammation
Verderio, C., Muzio, L., Turola, E., Bergami, A., Novellino, L., Ruffini, F., Riganti, L., Corradini, I., Francolini, M., Garzetti, L., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23627 · Cited by 326
Self-citationPlacebo-controlled trial of an oral BTK inhibitor in multiple sclerosis
Montalban, X., Arnold, D. L., Weber, M. S., Staikov, I., Piasecka-Stryczynska, K., Willmer, J., Martin, E. C., Dangond, F., Syed, S., & Wolinsky, J. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901981 · Cited by 324
Self-citationFoster, C. A., Howard, L. M., Schweitzer, A., Persohn, E., Hiestand, P. C., Balatoni, B., Reuschel, R., Beerli, C., Schwartz, M., & Billich, A. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.127183 · Cited by 322
Fingolimod for Multiple Sclerosis
Pelletier, D., & Hafler, D. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmct1101691 · Cited by 315
Neurodegeneration in multiple sclerosis and neuromyelitis optica
Kawachi, I., & Lassmann, H. (2017) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-313300 · Cited by 283
MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
Sormani, M. P., & Bruzzi, P. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70103-0 · Cited by 278
Fingolimod for the Treatment of Intracerebral Hemorrhage: A 2-Arm Proof-of-Concept Study
Fu, Y., Hao, J., Zhang, N., Ren, L., Sun, N., Li, Y.-J., Yan, Y., Huang, D., Yu, C., & Shi, F.-D. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1065 · Cited by 278
Fingolimod (FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar Slices
Miron, V. E., Ludwin, S. K., Darlington, P. J., Jarjour, A. A., Soliven, B., Kennedy, T. E., & Antel, J. P. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091234 · Cited by 267
Self-citationSignaling by internalized G-protein-coupled receptors
Calebiro, D., Nikolaev, V. O., Persani, L., & Lohse, M. J. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.02.002 · Cited by 266
FTY720 modulates human oligodendrocyte progenitor process extension and survival
Miron, V. E., Jung, C. G., Kim, H. J., Kennedy, T. E., Soliven, B., & Antel, J. P. (2008) · Annals of Neurology · doi:10.1002/ana.21227 · Cited by 255
Self-citationPharmacologic Treatment of Acute Kidney Injury: Why Drugs Haven’t Worked and What Is on the Horizon
Jo, S. K., Rosner, M. H., & Okusa, M. D. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03280906 · Cited by 252
Wheeler, D., Bandaru, V. V. R., Calabresi, P. A., Nath, A., & Haughey, N. J. (2008) · Brain · doi:10.1093/brain/awn190 · Cited by 171
“, 2007) and recent results from phase II trials with RRMS patients are promising (Kappos et al., 2006).”
BackgroundResultChun, J., Kihara, Y., Jonnalagadda, D., & Blaho, V. A. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021358 · Cited by 131
“A proof-ofconcept phase II study demonstrated efficacy as a monotherapy in MS (1) at transplant dosing levels (1.”
BackgroundPröbstel, A.-K., & Baranzini, S. E. (2018) · Neurotherapeutics · doi:10.1007/s13311-017-0587-y · Cited by 110
Vascular and immunobiology of the circulatory sphingosine 1-phosphate gradient
Yanagida, K., & Hla, T. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021014-071635 · Cited by 109
Brain modulation by the gut microbiota: From disease to therapy
Mitra, S., Dash, R., Nishan, A. A., Habiba, S. U., & Moon, I. S. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2022.12.001 · Cited by 91
Immunomodulatory therapies delay disease progression in multiple sclerosis
Bergamaschi, R., Quaglini, S., Tavazzi, E., Amato, M. P., Paolicelli, D., Zipoli, V., Romani, A., Tortorella, C., Portaccio, E., D’Onghia, M., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458512445941 · Cited by 71
Fingolimod (FTY720) as an acute rescue therapy for intraocular inflammatory disease
Raveney, B. J. E., Copland, D. A., Nicholson, L. B., & Dick, A. D. (2008) · Archives of Ophthalmology · doi:10.1001/archopht.126.10.1390 · Cited by 39
Metadata
- Authors
- Kappos, L., Antel, J., Comi, G., Montalban, X., O'Connor, P., Polman, C. H., Haas, T., Korn, A. A., Karlsson, G., & Radue, E. W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-14
- Volume
- 355
- Issue
- 11
- Pages
- 1124-1140
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1992656196
- Cited by
- 1,054
- References
- 34
- FWCI
- 55.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.